Asciminib, a novel allosteric inhibitor of BCR‐ABL1, shows synergistic effects when used in combination with imatinib with or without drug resistance

• Main Authors: Naoki Okamoto (Author), Kenta Yagi (Author), Sayaka Imawaka (Author), Mayu Takaoka (Author), Fuka Aizawa (Author), Takahiro Niimura (Author), Mitsuhiro Goda (Author), Koji Miyata (Author), Kei Kawada (Author), Yuki Izawa‐Ishizawa (Author), Satoshi Sakaguchi (Author), Keisuke Ishizawa (Author)
• Format: Book
• Published: Wiley, 2024-08-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Abstract In the treatment of chronic myeloid leukemia (CML), resistance to BCR‐ABL inhibitors makes it difficult to continue treatment and is directly related to life expectancy. Therefore, asciminib was introduced to the market as a useful drug for overcoming drug resistance. While combining molecu...